Pharmacotherapeutic group: S10AA04 - hypolipidemic zasoby.Inhibitory HMG-CoA row The main pharmaco-therapeutic action: the hypolipidemic effect; holesterynznyzhuyuchyy synthetic agent, is a competitive inhibitor of HMG CoA reductase, does the main action in the liver and is mainly ratsematom erytroenantiomeriv two, one of which has pharmacological activity, inhibition of cholesterol biosynthesis reduces its content in liver cells, which stimulates the synthesis LDL receptors and thus enhances the capture of particles of LDL, the end result of such mechanisms is to reduce the concentration row in plasma, reduces total cholesterol (total Chemiluminescence), low density lipoprotein cholesterol (LDL), apolipoprotein B (APO B), and triglycerides (TG) and slightly increases high density lipoprotein cholesterol (HDL) in patients with hypercholesterolemia and mixed dyslipidemia; set for 2 weeks therapeutic response, and maximum response row achieved within 4 weeks after initiation of treatment row stabilized during prolonged therapy. The main pharmaco-therapeutic action: the hypolipidemic effect of the impact on lipid profile mediated receptor activation, which peroxisome proliferative activated factor type ? (PPAR?) via activation Lipoprotein PPAR? increases the intensity of drug lipolysis and withdrawal from plasma particles rich in triglycerides by lipase activation lipoproteyinovoyi and reduce the formation of apoproteyinu SIII; PPFR? activation also leads to increased synthesis of AI and AII apoproteyiniv; the above effects of fenofibrate lipoproteins in reducing fractions lipoproteyinov very low and low density (VLDL and LDL) containing apoproteyin B, and increasing fraction of high density lipoprotein (HDL), containing AI and AII apoproteyiny, in addition, by modifying the synthesis and catabolism of VLDL fraction fenofibrate increases LDL clearance and reduces the number of low LDL density level is elevated in patients at risk of coronary heart disease (lipid profile atherogenous). Side effects and complications in the use of drugs: abdominal pain, constipation, bloating, asthenia, headache, myopathy; nausea, diarrhea, skin rash, indigestion, itching, row dizziness, cramps, myalgia, pancreatitis, paresthesia, peripheral neuropathy, vomiting and anemia, rhabdomyolysis and hepatitis / jaundice; expressed c-m hypersensitivity, row occurs angioedema, vovchakopodibnym row polymyalgia rheumatica, vasculitis, thrombocytopenia, eosinophilia, ESR increase, arthritis, arthralgia, urticaria, changes in laboratory parameters row sometimes significant and sustained row levels serum transaminases, alkaline phosphatase Artificial Insemination or Aortic Insufficiency gamma-hlyutamil transpeptydazy, increased serum levels of Creatine musculoskeletal origin. Method of production of drugs: Table., Coated with Left Ventricular Failure mg. Method of production of drugs: Table., Coated tablets 5 mg, 10 mg, 20 mg, 40 mg, 80 mg. Dosing and drug doses: doses - from 5 to 80 mg should be used 1 p row day evening, when selecting the dose of changes should be done at intervals of not less than 4 weeks to achieve MDD 80 mg, taken by 1 p / day in the evening hours; standard starting dose in patients with high risk of CHD (combined with or without hyperlipidemia), patients for diabetes, patients with stroke or other cerebrovascular diseases in history, patients with diseases peripheral vessels as well as for patients with coronary artery disease - is 40 mg / day once in the row drug therapy can start simultaneously with Pre-eclampsia use of diet and exercise therapy, patients with hypercholesterolemia (not included in above categories of risk) - to the treatment by the patient should be standard hipoholesterynovu diet that should continue throughout the course of treatment, usually starting dose is 20 mg / day, which assigned once in the evening, for patients who need large (more than 45%) lower LDL, the initial dose may be 40 mg 1 p / day, evening, patients with mild or moderate hypercholesterolemia - starting dose 10 mg; patients with homozygous familial hypercholesterolemia, recommended 40 mg / day, which is used once in the evening, or 80 mg / day in 3 receptions (20 Calcium in the morning, afternoon and 20 mg 40 mg evening), in addition to another treatment that reduces cholesterol or row other treatment, if available, medication Voluntary Counselling and Testing Centers effective as monotherapy and in combination with sekvestrantamy bile acids.
ไม่มีความคิดเห็น:
แสดงความคิดเห็น